Best Women Health Companies in California, United States

DARE BIOSCIENCE is a developer of non-hormonal pharmaceutical products for female contraceptives. Their lead candidate, Ovaprene, is an intravaginal non-hormonal ring, that can provide contraceptive protection over several weeks. The design of the ring has a permeable mesh in the centre of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The spermiostatic agents are ascorbic acid and ferrous gluconate, which create pH buffering and immobilization of sperm.

Funding rounds

• Nov 2025Grant (prize money)$3.6M
• Feb 2025Grant (prize money)$2.3M
• Dec 2024Grant (prize money)$1M
• Jan 2024Grant (prize money)$750K

Founders & team

Sabrina JohnsonPresident and CEO

Investors

NICHD, Gates, NIH, HHS

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services

Developer of embryology diagnosis device for professionals. It offers DaVitri an automated platform designed to modernize egg freezing and embryo warming workflows, automates critical timing and cryoprotectant exposure steps for improved consistency and oocyte survival rates. It also offers m|z test an AI powered metabolomic test designed for non-invasive embryo selection.

Funding rounds

• Nov 2025Conventional Debt$23M
• Apr 2025Series C$20.6M
• May 2021Series B$15M
• Dec 2018Series A$13.6M

Founders & team

Jose HorcajadasCo-Founder & Chief Scientific OfficerSantiago MunneCo-Founder & CIOMartin VarsavskyCo-Founder & Chairman

Investors

Octopus Ventures, Google Ventures, Khosla Ventures, Felicis Ventures, Overwater Ventures, European Investment Bank

Tech stack

Amazon CloudfrontAmazon S3Amazon Web ServicesCdnjsCloudflareCloudflare Bot Management

Developer of sexual and reproductive health therapeutics. It offers two drug products which include PHEXXI vaginal gel that provides women with an in-the-moment contraceptive that maintains the baseline vaginal pH environment and SOLOSEC (secnidazole) which is used to treat bacterial vaginosis in women and the STI trichomoniasis in both men and women.

Funding rounds

• Jun 2025Post IPO$925K
• Apr 2025Post IPO$750K
• Sep 2023Post IPO$2.9M
• Feb 2023Post IPO$1.4M

Founders & team

Saundra PelletierCEO ► Phexxi ► Solosec

Investors

Woodford Investment Management, Invesco Mutual Fund, Adjuvant Capital, Keystone Capital, Walleye, Pinz Capital Management

Provider of non-invasive diagnostic tests for pregnant women. The company offers blood test-based diagnostics to predict the fetal development and health conditions of prenatal babies. They perform the detection of nine cell-free RNA (cfRNA) which help in measuring the gestational age of the fetal. The other non-invasive tests in which the maternal blood is analyzed for the cRNA to detect the preterm risk management solutions(advance of labor) in women.

Funding rounds

• Jul 2025Series B$23.7M
• Aug 2023Grant (prize money)$4.6M
• May 2022Conventional Debt—
• May 2022Series B$60M

Founders & team

Mads MelbyeCo-FounderManeesh JainCo-Founder & CEOManfred LeeChief Operating Officer

Investors

Comerica, Decheng Capital, BlackRock, Foresite Capital, General Catalyst, Google Ventures

Provider of cell-free cancer liquid biopsy test. The company provides a molecular counter platform to count the DNA molecules from blood samples. It provides genetic tests for cystic fibrosis, spinal muscular atrophy, sickle cell disease, etc.

Funding rounds

• Jun 2024Series D$130M
• Dec 2022Conventional Debt—
• Dec 2022Series C$48.5M
• Mar 2022Series C$125M

Founders & team

Oguzhan AtayCo-Founder & CEO

Investors

500 Global, Hummingbird Ventures, Neotribe, Libertus Capital, Pacific 8 Ventures, Y Combinator

Tech stack

Apple Icloud MailCdnjsCloudflareCookieyesGoogle AnalyticsGoogle Font Api

Wearable double electric breast pump kits. The company provides breast-pumps, bras, pumping accessories, bags, and body care products. Its pumping systems are connected by mobile application.

Funding rounds

• Jan 2024Series D$81.4M
• Apr 2021Series C$26.8M
• Sep 2020Series C$55M
• Dec 2019Series B$20M

Founders & team

John ChangCo-Founder & Chief Technical OfficerJosh MakowerFounder & ChairmanSarah OLearyCEO

Investors

New Enterprise Associates, Meritech, Lightstone Ventures, Perceptive Advisors, Endeavour Vision, Pura Vida Investments

Tech stack

Apple Icloud MailApple PayAuraBootstrapCart FunctionalityCloudflare

Developer of minimally invasive treatment for uterine fibroids. It has developed an ablation device for the treatment of uterine fibroids. The Sonata system includes a sonography probe at the tip of a radiofrequency ablation device. It is designed to image and treat fibroids inside the uterus without any incisions. The product is CE Mark approved.

Materna Medical provides a device for women’s pelvic health. It develops devices Milli, a vaginal and pelvic floor dilator, and Materna Prep, to reduce maternal childbirth-related injuries, like perineal lacerations, during vaginal delivery.

Funding rounds

• May 2024Series B$20M
• Jul 2022Series B$22M
• Apr 2021Series A$10M
• Oct 2019Grant (prize money)$50K

Founders & team

Michael StewartCo-FounderMark JuravicCo-FounderTracy MacnealPresident and CEO

Investors

Wavemaker 360, Womens VC Fund II, Golden Seeds, Black Capital, Shatter Fund, Band of Angels

Tech stack

Cart FunctionalitySquarespace CommerceSquarespaceStimulusGoogle AnalyticsPriority Hints

Manufacturer of medical devices for tracking cervical mucus fertility metrics. This device utilizes sensing technology to monitor vaginal fluid changes to assist with identifying fertile windows. The hardware integrates with a mobile application to provide data analysis regarding ovulation probability. Additionally, the device includes functionality for performing pelvic floor muscle exercises.

Funding rounds

• Jan 2025Series A$6.5M
• Sep 2021Seed$3M
• Jun 2018Seed—

Founders & team

Kristina CahojovaFounder & CEO

Investors

HAX, SOSV, Texas Halo Fund, Eacapmgmt, Ad Astra Ventures, VIENTO Ventures

Tech stack

Apache Http ServerApple PayAwinCart FunctionalityCloudflareCloudflare Browser Insights

Developer of a non-invasive fetal monitoring device. The company has developed a proprietary platform technology to monitor fetal health during labor and delivery.

Funding rounds

• May 2025Grant (prize money)$1.2M
• May 2020Grant (prize money)$225K

Founders & team

Soheil GhiasiCo-Founder

Investors

America’s Seed Fund, National Science Foundation

Developer of noninvasive sensor technology for fetal oxygen level monitoring. The company focuses on creating a fetal pulse oximeter for healthcare professionals. The aim is to provide a more accurate method to evaluate fetal oxygenation. The technology is intended to improve sensitivity and specificity when detecting fetal distress.

Funding rounds

• May 2024Series A$7.5M
• Feb 2023Series A—
• Jul 2021Series A$5M
• Aug 2020Grant (prize money)$999.4K

Founders & team

Neil RayFounder & CEO

Investors

Cross Border Impact Ventures, Global Health Impact Network, VCapital, March of Dimes, RH Capital, America’s Seed Fund

Innovating minimally invasive solutions for women's uterine health and well-being. This company focuses on developing and delivering best-in-class technology for diagnosing and treating Abnormal Uterine Bleeding (AUB). They offer a complete suite of minimally invasive devices designed for safety, simplicity, and successful outcomes. Their product suite includes solutions for endometrial ablation, fibroid and polyp removal, and diagnostic hysteroscopy. They provide dedicated support, training, and education for healthcare professionals and staff. The company is committed to continuous improvement, data transparency, and customer-centric service, ensuring the best possible patient experience. They are dedicated to advancing gynecologic surgery through device-enabled innovations in women’s health, targeting the root causes of AUB with efficient and effective treatments.

Funding rounds

• Feb 2023Post IPO—
• May 2020Conventional Debt$15M
• Nov 2019Conventional Debt$10M
• May 2019Series C$10.2M

Founders & team

David ClapperCEO

Investors

Accelmed, New Enterprise Associates, Versant Ventures, Novo Holdings, Vivo Capital

Tech stack

Amazon Web ServicesAnimate.CssAnime.JsCdnjsCloudflareCloudflare Bot Management